Inhibitory effect of recombinant human endostatin combined with rAd/p53 on graft model of human breast cancer in nude mice
- VernacularTitle:重组人血管内皮抑素联合重组人p53腺病毒治疗乳腺癌的实验性研究
- Author:
Guangzhang ZHAO
;
Xiaodong QI
;
Zhikun CHANG
- Publication Type:Journal Article
- Keywords:
endostatin;
p53;
breast cancer;
nude mice
- From:
China Oncology
2006;0(11):-
- CountryChina
- Language:Chinese
-
Abstract:
Background and purpose:There is a tendency to treat tumors through multiple genes and multiple targeting but there has been no reports about the therapeutic effect of recombinant human endostatin(ES)combined with rAd/p53 on graft model of human breast cancer.Methods:MCF-7 human breast cancer cells were inoculated in nude mice.Then the nude mice with xenograft tumor were randomized into groups of control,ES,rAd/p53,and ES + rAd/p53,they were treated according to the plan.Diversity of the xenograft tumor volume and side effect was observed.Microvessel density(MVD)and expression of vascular endothelial growth factor(VEGF)were detected by immunohistochemistry.Results:After the administration of ES,rAd/p53,ES + rAd/p53,the growth of tumor was inhibited with the inhibitory rate of 1.75%,43.36% and 58.68%,respectively.Inhibition of tumor growth was significant in Group rAd/p53 and ES + rAd/p53(P0.05).Conclusions:recombinant human endostatin combined with rAd/p53 can greatly inhibit growth of xenograft tumor,and reduce the generation of capillary vessels.
